Polyrizon Ltd.(PLRZ)

Biotechnology · Ra'anana, TA

$9.64+0.38 (+4.13%)

Delayed quote: Oct 6, 2026, 3:32 PM EDT

EV/Sales Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter revenue. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/Sales ratio is N/A as of 2026-10-06T19:37:52.737Z.

Stored calculation inputs

Calculation as of: 2026-10-06T19:37:52.737Z.

Quote observation: 2026-10-06T19:32:46.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 10,801,513
Total debt · period ending 2026-06-30: 0
Cash · period ending 2026-06-30: 8,410,000
TTM revenue · period ending 2026-06-30: N/A

FMP input reference: 94b5ad3735cc71b9af2236876c301d5f64b1c42b83610b62f031870796dba4d5

EV/EBITDA|P/S Ratio|Revenue|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

PLRZ EV/Sales Ratio Metrics

EV/SALES RATIO

N/A

PLRZ Competitors' EV/Sales Ratio

PLRZ

Polyrizon Ltd.

Current

Market Cap

$10.80M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

ADIL

Adial Pharmaceuticals, Inc.

vs PLRZ

Market Cap

$10.92M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

LSTA

Lisata Therapeutics, Inc.

vs PLRZ

Market Cap

$10.65M

EV/Sales Ratio

2.11x

TTM Avg

63.85x

3Y Avg

37.14x

5Y Avg

37.14x

BIVI

BioVie Inc.

vs PLRZ

Market Cap

$11.01M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

PLUR

Pluri Inc.

vs PLRZ

Market Cap

$11.06M

EV/Sales Ratio

41.78x

TTM Avg

47.52x

3Y Avg

96.27x

5Y Avg

132.69x

KPRX

Kiora Pharmaceuticals, Inc.

vs PLRZ

Market Cap

$11.12M

EV/Sales Ratio

N/A

TTM Avg

2.30x

3Y Avg

2.30x

5Y Avg

5910.26x

GDTC

CytoMed Therapeutics Limited

vs PLRZ

Market Cap

$10.46M

EV/Sales Ratio

N/A

TTM Avg

30.14x

3Y Avg

54.00x

5Y Avg

56.96x

VTGN

VistaGen Therapeutics, Inc.

vs PLRZ

Market Cap

$11.19M

EV/Sales Ratio

N/A

TTM Avg

95.17x

3Y Avg

42.02x

5Y Avg

108.43x

MSLE

Satellos Bioscience Inc.

vs PLRZ

Market Cap

$10.40M

EV/Sales Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CNSY

Cerenome, Inc.

vs PLRZ

Market Cap

$11.22M

EV/Sales Ratio

2.12x

TTM Avg

3.91x

3Y Avg

3.91x

5Y Avg

3.91x

NAME	MARKET CAP	EV/SALES RATIO	TTM	3Y	5Y
Polyrizon Ltd. (PLRZ)	$10.80M	N/A	N/A	N/A	N/A
Adial Pharmaceuticals, Inc. (ADIL)vs ›	$10.92M	N/A	N/A	N/A	N/A
Lisata Therapeutics, Inc. (LSTA)vs ›	$10.65M	2.11x	63.85x	37.14x	37.14x
BioVie Inc. (BIVI)vs ›	$11.01M	N/A	N/A	N/A	N/A
Pluri Inc. (PLUR)vs ›	$11.06M	41.78x	47.52x	96.27x	132.69x
Kiora Pharmaceuticals, Inc. (KPRX)vs ›	$11.12M	N/A	2.30x	2.30x	5910.26x
CytoMed Therapeutics Limited (GDTC)vs ›	$10.46M	N/A	30.14x	54.00x	56.96x
VistaGen Therapeutics, Inc. (VTGN)vs ›	$11.19M	N/A	95.17x	42.02x	108.43x
Satellos Bioscience Inc. (MSLE)vs ›	$10.40M	N/A	N/A	N/A	N/A
Cerenome, Inc. (CNSY)vs ›	$11.22M	2.12x	3.91x	3.91x	3.91x

Understanding EV/Sales

Enterprise Value (EV) = Market Cap + Total Debt - Cash

Sales = Total Revenue (TTM)

EV/Sales is commonly used because:

It works for unprofitable companies where P/E doesn't apply
Revenue is harder to manipulate than earnings
It supports comparisons across companies at different profitability stages
It is frequently used for software and other revenue-growth-focused companies

Note: EV/Sales does not include margin, debt maturity, cash conversion, or growth durability by itself.

EV/Sales Ratio Formula & Definition

EV/Sales = Enterprise Value / Revenue (TTM)

Enterprise value to sales compares total company value to revenue, useful across capital structures and for unprofitable companies.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

EV/EBITDA P/S Ratio Revenue All Metrics